PK//PD/Tolerability Study of DA-1229(Evogliptin) in Renal Impaired Patients
NCT ID: NCT02214693
Last Updated: 2015-08-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2014-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Pharmacokinetics/Pharmacodynamics and Safety/Tolerability of Evogliptin in Hemodialysis Patients
NCT04195919
Study to Evaluate the Safety and Pharmacokinetics of CKD-349 in Healthy Adult Volunteers
NCT05089279
A Study of LY3819469 in Participants With Impaired and Normal Renal Function
NCT05841277
A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
NCT05379829
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate in Patients With Stable Severe Renal Disease.
NCT01711853
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1(Severe decrease in GFR)
Severe decrease in GFR
DA-1229
Group 2(Moderate decrease in GFR)
Moderate decrease in GFR
DA-1229
Group 3(Mild decrease in GFR)
Mild decrease in GFR
DA-1229
Group 4(Normal GFR)
Normal GFR
DA-1229
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DA-1229
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Weights between 50 and 90kg(Female : 40 and 90kg)
* Volunteer who totally understands the progress of this clinical trials, makes decision by his free will, and signed a consent form to follow the progress
* Stable results of estimated GFR in 4 months recently
Exclusion Criteria
* Volunteer who had drug(DPP-4 inhibitor) hypersensitivity reaction
* Volunteer who already participated in other trials in 2 months
* Volunteer who had whole blood donation in 2 months, or component blood donation in 1 months or transfusion
20 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dong-A ST Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clinical Trial Center, Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA1229_RI_I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.